Skinvisible Pharmaceuticals, Inc.

Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis along with sunscreens, anti-aging products,

alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®. Skinvisible's primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products. Click here to see current licensees.

The Technology: Invisicare® offers numerous benefits including binding products to the skin for 4 hours+ and more, while resisting wash-off and rub-off. It also enhances the efficacy of ingredients, reduces irritation and can reduce costs. Skinvisible has developed a portfolio of 25+ skincare products using Invisicare and also works directly with companies to enhance their products, especially ones coming off patent. Learn more at www.invisicare.com .
(Note: These are not approved claims in Canada)

Intellectual Property: Skinvisible's value lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. Patent approvals are sought (in the U.S. and internationally) for all products developed. There are six patents approved, including three in the US, and internationally in China, India, Australia, Japan and Korea. There are a number of U.S. patents pending in addition to PCTs internationally, with many more to be filed. Some of these PCT patents cover up to five products. All patents with Invisicare are owned by Skinvisible. Click here to learn more about our patents.

The Opportunity: Pharmaceutical companies pursue new or improved revenue streams along with protecting their own patented products. New product formulations are expensive and time intensive for companies to undertake. Invisicare allows companies to sell a patent-protected product that has been revitalized with new benefits, providing a new story to help combat generic competitors. A perscription dermatology product can generate $100+ million per year; many even more - that's why a pharmaceutical company's investment into an Invisicare formulated product is a very viable option.

New Product Spotlight:

Latest News:

SKINVISIBLE TRADES EXCLUSIVELY ON OTCQB

October 12, 2011
Skinvisible’s DermSafe Hand Sanitizer Recommended by the Dermatology Review Panel - Alcohol-free Hand Sanitizer with Invisicare Receives Dermatologists’ Seal of Approval

September 22, 2011
Skinvisible Receives European Patent Notice for Invisicare - Drug Delivery Technology Protected on Four Continents

August 18, 2011
Skinvisible's DermSafe Hand Sanitizer to Launch in Canada - Hand Sanitizer Made Without Alcohol Available Just in Time for Flu Season

July 18, 2011
Skinvisible Licensee Launches First Prescription Product in the USA - Womens Choice Pharmaceuticals Introduces ProCort® Hemorrhoid Treatment

April 27, 2011
Skinvisible Licensee Receives First European Approval for Hand Sanitizer - Rhei Pharmaceuticals to Launch HandSafe in Belgium

Skinvisible Shareholder Update 2011

CLICK HERE TO READ ALL NEWS RELEASES

Sign up for Skinvisible Inc. Updates:

Click here to join our mailing list.